D.E. Shaw & Co’s Aprea Therapeutics APRE Stock Holding History

D.E. Shaw & Co’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,488	Closed	-$37K	–	5163
2022 Q2	$37K	Buy	2,488 +1,644	+195%	+$37.9K	﹤0.01%	4896
2022 Q1	$31K	Buy	+844	New	+$34.6K	﹤0.01%	5259

Other funds holding APRE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's APRE Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Aprea Therapeutics (APRE) in Q3 2022, closing a stake of 2,488 shares — an estimated $37K sold.

D.E. Shaw & Co first reported a position in APRE in Q1 2022 and held it in 2 quarters. The position peaked at $37K in Q2 2022. 26 funds tracked by Wall St. Rank hold APRE as of Q3 2022.

D.E. Shaw & Co reported no remaining Aprea Therapeutics position as of Q3 2022 after selling out during the quarter.
D.E. Shaw & Co sold 2,488 Aprea Therapeutics shares in Q3 2022, an estimated $37K.
D.E. Shaw & Co first reported a position in Aprea Therapeutics in Q1 2022 and held it in 2 quarters.
D.E. Shaw & Co's Aprea Therapeutics position peaked at $37K in Q2 2022.
26 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.